Title | Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Xu S, Chaudhary O, Rodríguez-Morales P, Sun X, Chen D, Zappasodi R, Xu Z, Pinto AFM, Williams A, Schulze I, Farsakoglu Y, Varanasi SKarthik, Low JSiong, Tang W, Wang H, McDonald B, Tripple V, Downes M, Evans RM, Abumrad NA, Merghoub T, Wolchok JD, Shokhirev MN, Ho P-C, Witztum JL, Emu B, Cui G, Kaech SM |
Journal | Immunity |
Volume | 54 |
Issue | 7 |
Pagination | 1561-1577.e7 |
Date Published | 2021 Jul 13 |
ISSN | 1097-4180 |
Keywords | Animals, Biological Transport, CD36 Antigens, CD8-Positive T-Lymphocytes, Cell Line, Tumor, HEK293 Cells, Humans, Leukocytes, Mononuclear, Lipid Peroxidation, Lipoproteins, LDL, Lymphocytes, Tumor-Infiltrating, Mice, Mice, Inbred C57BL, Mice, Transgenic, Neoplasms, Receptors, Scavenger, Tumor Microenvironment |
Abstract | A common metabolic alteration in the tumor microenvironment (TME) is lipid accumulation, a feature associated with immune dysfunction. Here, we examined how CD8+ tumor infiltrating lymphocytes (TILs) respond to lipids within the TME. We found elevated concentrations of several classes of lipids in the TME and accumulation of these in CD8+ TILs. Lipid accumulation was associated with increased expression of CD36, a scavenger receptor for oxidized lipids, on CD8+ TILs, which also correlated with progressive T cell dysfunction. Cd36-/- T cells retained effector functions in the TME, as compared to WT counterparts. Mechanistically, CD36 promoted uptake of oxidized low-density lipoproteins (OxLDL) into T cells, and this induced lipid peroxidation and downstream activation of p38 kinase. Inhibition of p38 restored effector T cell functions in vitro, and resolution of lipid peroxidation by overexpression of glutathione peroxidase 4 restored functionalities in CD8+ TILs in vivo. Thus, an oxidized lipid-CD36 axis promotes intratumoral CD8+ T cell dysfunction and serves as a therapeutic avenue for immunotherapies. |
DOI | 10.1016/j.immuni.2021.05.003 |
Alternate Journal | Immunity |
PubMed ID | 34102100 |
PubMed Central ID | PMC9273026 |
Grant List | S10 OD021815 / OD / NIH HHS / United States R01 HL105278 / HL / NHLBI NIH HHS / United States R01 CA206483 / CA / NCI NIH HHS / United States P42 ES010337 / ES / NIEHS NIH HHS / United States R01 DK120480 / DK / NIDDK NIH HHS / United States P30 CA030199 / CA / NCI NIH HHS / United States R00 HL148504 / HL / NHLBI NIH HHS / United States RF1 AG064049 / AG / NIA NIH HHS / United States P30 CA023100 / CA / NCI NIH HHS / United States R37 DK057978 / DK / NIDDK NIH HHS / United States R01 CA240909 / CA / NCI NIH HHS / United States K99 HL148504 / HL / NHLBI NIH HHS / United States R01 HL148188 / HL / NHLBI NIH HHS / United States R01 DK057978 / DK / NIDDK NIH HHS / United States R01 GM102491 / GM / NIGMS NIH HHS / United States P30 CA014195 / CA / NCI NIH HHS / United States |